-
公开(公告)号:US20050026914A1
公开(公告)日:2005-02-03
申请号:US10891636
申请日:2004-07-13
申请人: John Buchanan , Daniel Elbaum , Matthew Martin , David McGowan , Perry Novak , Joseph Nunes
发明人: John Buchanan , Daniel Elbaum , Matthew Martin , David McGowan , Perry Novak , Joseph Nunes
IPC分类号: A61P37/00 , C07D213/75 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , A61K31/541 , A61K31/506 , A61K31/5377 , C07D413/02 , C07D417/02 , C07
CPC分类号: C04B35/632 , C07D213/75 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要: The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I: and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.
摘要翻译: 本发明涉及具有通式I的嘧啶或吡啶氨基甲酸酯化合物及其药学上可接受的盐或衍生物。 还包括治疗各种疾病和病症的方法,包括炎症,T细胞活化和增殖的抑制,关节炎,器官移植,缺血或再灌注损伤,心肌梗塞,中风,多发性硬化,炎性肠病,克罗恩病,狼疮, 超敏反应,1型糖尿病,牛皮癣,皮炎,桥本甲状腺炎,干燥综合征,自身免疫性甲状腺功能亢进,艾迪生病,自身免疫性疾病,肾小球性肾炎,过敏性疾病,哮喘,干草病,湿疹,癌症,结肠癌,胸腺瘤,仅举几例 哺乳动物,所述方法包括给予治疗有效量的如上所述的式I化合物或其盐或衍生物形式。
-
公开(公告)号:US20060241115A1
公开(公告)日:2006-10-26
申请号:US11042634
申请日:2005-01-24
申请人: Michele Potashman , Tae-Seong Kim , Steven Bellon , Shon Booker , Yuan Cheng , Joseph Kim , Andrew Tasker , Ning Xi , Shimin Xu , Jean-Christophe Harmange , George Borg , Matthew Weiss , Brian Hodous , Russell Graceffa , William Buckner , Craig Masse , Deborah Choquette , Matthew Martin , Julie Germain , Lucian DiPietro , Stuart Chaffee , Joseph Nunes , John Buchanan , Gregory Habgood , David McGowan , Douglas Whittington
发明人: Michele Potashman , Tae-Seong Kim , Steven Bellon , Shon Booker , Yuan Cheng , Joseph Kim , Andrew Tasker , Ning Xi , Shimin Xu , Jean-Christophe Harmange , George Borg , Matthew Weiss , Brian Hodous , Russell Graceffa , William Buckner , Craig Masse , Deborah Choquette , Matthew Martin , Julie Germain , Lucian DiPietro , Stuart Chaffee , Joseph Nunes , John Buchanan , Gregory Habgood , David McGowan , Douglas Whittington
IPC分类号: A61K31/517 , A61K31/502 , A61K31/498 , A61K31/4709 , C07D43/02
CPC分类号: C07D213/64 , C07D213/81 , C07D215/233 , C07D215/38 , C07D215/48 , C07D215/54 , C07D237/34 , C07D239/34 , C07D239/47 , C07D239/84 , C07D239/94 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04
摘要: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
-
公开(公告)号:US20050107374A1
公开(公告)日:2005-05-19
申请号:US10969826
申请日:2004-10-20
申请人: Daniel Elbaum , Matthew Martin , Joseph Nunes
发明人: Daniel Elbaum , Matthew Martin , Joseph Nunes
IPC分类号: A61K31/505 , C07D403/04 , C07D473/12 , A61K31/52 , A61K31/5377 , A61K31/541
CPC分类号: C07D403/04
摘要: The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.
摘要翻译: 本发明涉及羟基苯并咪唑嘧啶或吡啶或其药学上可接受的盐。 还包括治疗炎症,抑制T细胞活化和增殖,关节炎,类风湿性关节炎,银屑病关节炎,骨关节炎,器官移植,急性移植或异种移植或同种移植物排斥,移植耐受性诱导,缺血或再灌注损伤,心肌梗死的方法 ,中风,多发性硬化,炎症性肠病,包括溃疡性结肠炎,克罗恩病,狼疮,接触性超敏反应,迟发型超敏反应和麸质敏感性肠病,1型糖尿病,牛皮癣,接触性皮炎,桥本氏甲状腺炎,干燥综合征,自身免疫性甲状腺功能亢进 ,艾迪生病,自身免疫性多腺病,自身免疫性脱发,恶性贫血,白癜风,自身免疫性低位症,吉兰巴利综合征,肾小球性肾炎,血清病,荨麻疹,过敏性疾病,哮喘,高粱,过敏性鼻炎,巩膜瘤,蕈样真菌病,皮肌炎,斑秃 ,慢性交感 包括给予治疗有效量的如上所述的化合物,包括给予治疗有效量的上述化合物,其中,所述治疗有效量的治疗有效量的药物组合物包括给予治疗有效量的上述化合物。
-
公开(公告)号:US20060046977A1
公开(公告)日:2006-03-02
申请号:US11184237
申请日:2005-07-18
申请人: Joseph Nunes , Matthew Martin , Ryan White , David McGowan , Jean Bemis , Frank Kayser , Jiasheng Fu , Jinqian Liu , Xian Jiao
发明人: Joseph Nunes , Matthew Martin , Ryan White , David McGowan , Jean Bemis , Frank Kayser , Jiasheng Fu , Jinqian Liu , Xian Jiao
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/4741 , C07F7/02 , C07D491/02 , A61K31/695
CPC分类号: C07D491/04 , C07D491/14
摘要: The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.
摘要翻译: 本发明涉及具有通式I的呋喃并吡啶化合物及其立体异构体,互变异构体,溶剂合物,药用盐和衍生物及其前药。 本发明还包括药物组合物,其包含式I化合物,调节Lck和ACK-1酶的方法以及治疗各种相关疾病和病症,包括炎症,T细胞活化抑制,增殖,关节炎,器官移植,缺血或再灌注 损伤,心肌梗塞,中风,多发性硬化,炎性肠病,克罗恩病,狼疮,超敏反应,1型糖尿病,牛皮癣,皮炎,桥本氏甲状腺炎,干燥综合征,自身免疫性甲状腺功能亢进,艾迪生病,自身免疫性疾病,肾小球肾炎,过敏性疾病,哮喘 ,干草组织,湿疹,癌症,结肠癌,胸腺瘤,仅举几个例子,在哺乳动物中,包括向哺乳动物施用治疗有效量的如上所述的式I化合物和制备包含以下化合物的药物的方法: 一级方程式
-
公开(公告)号:US20070054916A1
公开(公告)日:2007-03-08
申请号:US11240590
申请日:2005-09-30
申请人: Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
发明人: Vinod Patel , Joseph Kim , Stephanie Geuns-Meyer , Stuart Chaffee , Victor Cee , Brian Hodous , Steven Bellon , Jean-Christophe Harmange , Philip Olivieri , Maya Thaman , Erin DiMauro , John Buchanan , David McGowan , Brian Albrecht , Holly Deak , Jean Bemis , Ryan White , Matthew Martin , Gregory Habgood , Paul Tempest , Craig Masse , William Buckner , Bradley Herberich , Russell Graceffa , Dawei Zhang , Shimin Xu , Kelvin Sham , Robert Rzasa , James Falsey , Partha Chakrabarti , Guo-Qiang Cao , Susan Tomlinson , Liping Pettus , Adrian Smith , Nick Paras , Gang Liu , Frenel DeMorin , Andrew Tasker , Anthony Reed
IPC分类号: A61K31/525 , A61K31/519 , A61K31/517
CPC分类号: C07D215/38 , C07C205/37 , C07D215/12 , C07D217/12 , C07D217/22 , C07D217/26 , C07D239/26 , C07D239/84 , C07D239/94 , C07D239/95 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译: 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病,包括炎症,癌症和相关病症的化合物。 化合物具有通式I,其中A 1,A 2,A 3,B,R 1, R 2,R 3和R 4在本文中定义。 因此,本发明还包括含有本发明化合物的药物组合物,使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号:US20060217380A1
公开(公告)日:2006-09-28
申请号:US11251490
申请日:2005-10-14
申请人: Stuart Chaffee , Brian Albrecht , Brian Hodous , Matthew Martin , David McGowan , Erin DiMauro , Gade Reddy , Victor Cee , Philip Olivieri , Anthony Reed , Karina Romero
发明人: Stuart Chaffee , Brian Albrecht , Brian Hodous , Matthew Martin , David McGowan , Erin DiMauro , Gade Reddy , Victor Cee , Philip Olivieri , Anthony Reed , Karina Romero
IPC分类号: A61K31/517 , A61K31/5377 , A61K31/503
CPC分类号: C07D213/74 , C07D213/81 , C07D215/14 , C07D239/42 , C07D241/42 , C07D401/06 , C07D401/12 , C07D403/10 , C07D403/12 , C07D405/06 , C07D409/06 , C07D413/12 , C07D417/12 , C07D471/04
摘要: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, R1 and R2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译: 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病,包括炎症,癌症和相关病症的化合物。 化合物具有通式I,其中A 1,A 2,A 3,A 4,R 4, 本文定义了SUP> 1和R 2。 因此,本发明还包括含有本发明化合物的药物组合物,使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号:US20070072862A1
公开(公告)日:2007-03-29
申请号:US11503551
申请日:2006-08-11
申请人: Erin Dimauro , Jean Bemis , Stuart Chaffee , Ning Chen , Essu Hu , Roxanne Kunz , Matthew Martin , David McGowan , Shannon Rumfelt
发明人: Erin Dimauro , Jean Bemis , Stuart Chaffee , Ning Chen , Essu Hu , Roxanne Kunz , Matthew Martin , David McGowan , Shannon Rumfelt
IPC分类号: A61K31/506 , A61K31/502 , A61K31/501 , A61K31/497 , A61K31/498 , A61K31/4745 , A61K31/4709
CPC分类号: C07D213/75 , C07D215/38 , C07D239/42 , C07D239/48 , C07D239/50 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04
摘要: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.
摘要翻译: 本发明包括一类新的可用于预防和治疗蛋白激酶介导的疾病,包括自身免疫疾病和炎症的化合物。 在一个实施方案中,化合物具有通式I,其中A 1,A 2,A 3,A 4, >,L,R 1,R 2和R 3在本文中定义。 本发明还包括药物组合物,其包含一种或多种本发明化合物,通过施用本发明化合物来治疗Lck和/或c-Kit激酶介导的疾病的使用方法,或包含一种或多种本发明化合物的组合物 发明,以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号:US20230114741A1
公开(公告)日:2023-04-13
申请号:US17904793
申请日:2021-02-24
申请人: Kennon GUGLIELMO , Adam SCHUMANN , Brent LUDWIG , Matthew MARTIN , Bruno BALOCCO , Eric J. KASTANIS , EControls, LLC
发明人: Kennon Guglielmo , Adam Schumann , Brent Ludwig , Matthew Martin , Bruno Balocco , Eric J. Kastanis
IPC分类号: H02J7/14 , H01M10/0525 , H02J7/00 , H01M10/42 , H01M4/58 , H02J7/34 , B60R16/033
摘要: Disclosed embodiments involve a rechargeable lithium-ion battery module assembly for use as an auxiliary power unit (APU), particularly in commercial trucks. Battery module assembly is recharged through the semi-trailer truck's alternator during engine operation. Battery module assembly has active voltage control capabilities to reduce charge time. Each battery array has two collector plate printed circuit board assemblies (PCBA) and two banks of lithium iron phosphate (LFP) battery cells. Individual battery cells are wire bonded to the collector plate PCBs, one of such PCBs incorporates a battery management system to monitor the electrical parameters and state of charge of the battery cells in the system. Battery cells are thermally coupled to an aluminum enclosure with a thermal gap filling material. Using different chemistries for the APU and the starting battery of the commercial truck, and methods of sequential charge and discharge cycles of each, without any other discrete device.
-
公开(公告)号:US08766940B1
公开(公告)日:2014-07-01
申请号:US13454275
申请日:2012-04-24
IPC分类号: G06F3/041
CPC分类号: G06F3/041 , G06F2203/0339 , G06F2203/0381 , G06F2203/04809
摘要: A computing device includes a trackpad, which includes a touch-sensitive surface having a touch-detectable pattern. The touch-detectable pattern includes a first feature, and a second feature having first and second side features. The first and second side features start in proximity of the first feature and are positioned on opposite sides of the first feature.
摘要翻译: 计算设备包括触控板,其包括具有触摸可检测图案的触敏表面。 触摸可检测图案包括第一特征和具有第一和第二侧面特征的第二特征。 第一和第二侧面特征从第一特征开始并位于第一特征的相对侧。
-
公开(公告)号:US07772559B2
公开(公告)日:2010-08-10
申请号:US12232451
申请日:2008-09-17
申请人: Ziad Burbar , James Corbeil , Gregory Hayzen , Sridhar Kuppuswamy , Ralf Ladebeck , Matthew Martin , Matthias Schmand
发明人: Ziad Burbar , James Corbeil , Gregory Hayzen , Sridhar Kuppuswamy , Ralf Ladebeck , Matthew Martin , Matthias Schmand
IPC分类号: G01T1/164
CPC分类号: G01T1/1603 , A61B6/037 , G01T7/005
摘要: A method for stabilizing the gain of a PET detection system with a cooling unit includes: determining the temperature of at least one component of the PET detection system, comparing the actual gain with a reference value, and actuating the cooling unit to influence the temperature such that the gain tends to the reference value. In at least one embodiment, the reference value is determined by determining the temperature of the at least one component during a test measurement, determining the gain during the test measurement, determining a functional dependence of the gain on the temperature, and selecting the reference value based on the gain to be stabilized. Advantageously, in at least one embodiment the gain can be kept constant using the described method in a simple manner, with the influence of the temperature of the components being taken into account.
摘要翻译: 用于利用冷却单元稳定PET检测系统的增益的方法包括:确定PET检测系统的至少一个部件的温度,将实际增益与参考值进行比较,以及致动冷却单元以影响温度 增益趋于参考值。 在至少一个实施例中,参考值通过在测试测量期间确定至少一个组件的温度,确定测试测量期间的增益,确定增益对温度的功能依赖性以及选择参考值来确定 基于要稳定的收益。 有利地,在至少一个实施例中,利用所述方法以简单的方式,可以将增益保持恒定,同时考虑组件的温度的影响。
-
-
-
-
-
-
-
-
-